Advertisement

The metabolism of deuterium-labelled p-tyramine in man

  • R. A. D. Jones
  • C. R. Lee
  • R. J. Pollitt

Abstract

In recent years interest in the metabolism of p-tyramine in man has been stimulated by its possible role in migraine (Hanington, 1967), in hepatic encephalopathy (Faraj et al., 1976) and in the hypertensive crises experienced by some subjects taking monoamine oxidase inhibitors (Blackwell, 1963). It has also been reported that pressor response to infused tyramine is higher in endogenous depression (Ghose, Turner and Koppen, 1975). A number of studies using unlabelled tyramine (Horowitz et al., 1964; Youdim et al., 1971; Smith and Mitchell, 1974) and 14C-labelled tyramine (Smith, March and Gordon, 1972; Boulton and Marjerrison, 1972; Tacker, Creaven and McIsaac, 1972) have been performed in man. They have revealed that the major pathways of metabolism are oxidation and conjugation and that a small proportion of the administered tyramine is excreted unchanged in the urine.

Keywords

Hepatic Encephalopathy Phenylacetic Acid Homovanillic Acid Urinary Acid Endogenous Depression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Axelrod, J., Inscoe, J. K. and Daly, J. (1965). J. Pharm. Exp. Ther., 149, 16Google Scholar
  2. Blackwell, B. (1963). Lancet, 2, 849CrossRefGoogle Scholar
  3. Boulton, A. A. and Marjerrison, G. L. (1972). Nature, 236, 76CrossRefGoogle Scholar
  4. Coppen, A., Brooksbank, B. W. L., Eccleston, E., Peet, M. and White, S. G. (1974). Psycho!. Med., 4, 164CrossRefGoogle Scholar
  5. Creveling, C. R., Levitt, M. and Udenfriend, S. (1962). Life Sci., 10, 523CrossRefGoogle Scholar
  6. Faraj, B. A., Bowen, P. A., Isaacs, J. W. and Rudman, D. (1976). New Engl. J. Med., 294, 1360CrossRefGoogle Scholar
  7. Ghose, K., Turner, P. and Coppen, A. (1975). Lancet, 1, 1317CrossRefGoogle Scholar
  8. Hanington, E. (1967). Brit. Med. J., 2, 550CrossRefGoogle Scholar
  9. Horowitz, D., Lovenberg, W., Engleman, K. and Sjoerdsma, A. (1964). J. Amer. Med. Assoc., 188, 1108Google Scholar
  10. Imaizumi, R., Yoshida, H., Hiramatsu, H. and Omori, K. (1958). Jap. J. Pharmacol., 8, 22CrossRefGoogle Scholar
  11. Jones, R. A. D. and Pollitt, R. J. (1976). J. Pharm. Pharmacol., 28, 461CrossRefGoogle Scholar
  12. Lee, C. R. (1976). Biomed. Mass Spectrom., 3, 48CrossRefGoogle Scholar
  13. Lemberger, L., Klutch, A. and Kuntzman, R. (1966). J. Pharm. Exp. Ther., 153, 183Google Scholar
  14. Lemberger, L., Kuntzman, R., Conney, A. H. and Burns, J. J. (1965). J. Pharm. Exp. Ther., 150, 292Google Scholar
  15. Smith, I., March, S. E. and Gordon, A. J. (1972). Clin. Chim. Acta, 40, 415Google Scholar
  16. Smith, I. and Mitchell, P. D. (1974). Biochem. J., 142, 189CrossRefGoogle Scholar
  17. Tacker, M., Creaven, P. J. and Mclsaac, W. M. (1972). J. Pharm. Pharmacol., 24, 247CrossRefGoogle Scholar
  18. Youdim, M. B. H., Bonham-Carter, S., Sandler, M., Hanington, E. and Wilkinson, M. (1971). Nature, 230, 127CrossRefGoogle Scholar

Copyright information

© The Contributors 1978

Authors and Affiliations

  • R. A. D. Jones
    • 1
  • C. R. Lee
    • 1
  • R. J. Pollitt
    • 1
  1. 1.MRC Unit for Metabolic Studies in Psychiatry, University Department of PsychiatryMiddlewood HospitalSheffieldUK

Personalised recommendations